Retatrutide, a experimental dual activator of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) binding site , is exhibiting promising outcomes in early human trials . Recent https://bookmarkprobe.com/story21635850/retatrutide-emerging-research-and-projected-clinical-roles